We all know that abiraterone acetate (Zytiga) plus prednisone provides a survival advantage for men with castrate resistant advanced prostate cancer (mCRPC) who have had prior treatment with a taxane based chemotherapy. New information has shown that abiraterone acetate offers a somewhat longer overall survival benefit than the data originally presented when the trial halted in 2010.

In a summary report on the MedPage Today web site it was reported that abiraterone acetate plus prednisone provided a median overall survival benefit of 4.6 months compared to a placebo plus prednisone. The final analysis of the Cougar Trial showed that, prior to any cross over from placebo to the treatment group the median survival of the men in the treatment group was 15.8 months while the placebo group plus prednisone had a median survival of 11.2 months, a 4.6 month advantage to